A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout.

about

A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout.

Item

http://www.wikidata.org/entity/Q51741961

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

A Beacon in the Dark: Canakinu ...... ve in Chronic Tophaceous Gout.

@en

A Beacon in the Dark: Canakinu ...... ve in Chronic Tophaceous Gout.

@nl

type

Item

label

A Beacon in the Dark: Canakinu ...... ve in Chronic Tophaceous Gout.

@en

A Beacon in the Dark: Canakinu ...... ve in Chronic Tophaceous Gout.

@nl

prefLabel

A Beacon in the Dark: Canakinu ...... ve in Chronic Tophaceous Gout.

@en

A Beacon in the Dark: Canakinu ...... ve in Chronic Tophaceous Gout.

@nl

P1476

A Beacon in the Dark: Canakinu ...... ve in Chronic Tophaceous Gout.

@en

P2093

Antonella De Santis

http://www.w3.org/2001/XMLSchema#string

Daniela Marotto

http://www.w3.org/2001/XMLSchema#string

Davide Firinu

http://www.w3.org/2001/XMLSchema#string

Donatella Chessa

http://www.w3.org/2001/XMLSchema#string

Stefano Del Giacco

http://www.w3.org/2001/XMLSchema#string

P2860

Gout-associated uric acid crystals activate the NALP3 inflammasome

2016 updated EULAR evidence-based recommendations for the management of gout.

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.

A Systematic Review of the Economic and Humanistic Burden of Gout.

Recent advances in crystal-induced acute inflammation.

Anakinra for the treatment of acute severe gout in critically ill patients.

Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.

Global epidemiology of gout: prevalence, incidence and risk factors.

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.

P2888

s40744-018-0104-8

P304

303-310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1007/S40744-018-0104-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29524120

http://www.w3.org/2001/XMLSchema#string

P932

5935617

http://www.w3.org/2001/XMLSchema#string